Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Promoting remyelination to prevent/reduce neurodegeneration in patients with multiple sclerosis (MS) is a major therapeutic goal. The longstanding view that the block of oligodendrocyte progenitor cell (OPC) differentiation in MS lesions is the leading cause of remyelination failure has inspired the scientific community to focus primarily on OPC differentiation-promoting compounds as pro-remyelinating agents. Yet, these strategies have been challenged by findings that active MS lesions contain surviving oligodendrocytes that may contribute to remyelination, while many chronic lesions contain low numbers of oligodendroglial cells. In addition, clinical trials using differentiation-stimulating drugs have shown limited efficacy. Thus, a strategic shift in the design of potential remyelination-promoting therapies may be required to achieve significant clinical benefits, which calls for a careful reconsideration of the mechanisms underlying remyelination failure in MS. Here, we argue that both the rate and the efficacy of OPC recruitment are fundamental determinants of remyelination, and that stimulating this process in MS may be crucial to achieve myelin regeneration. We first review different types of MS lesions in early and chronic MS, with a particular focus on OPCs and surviving oligodendrocytes. Based on the neuropathological findings and results obtained using models of demyelination, we make the case that OPC differentiation block in chronic MS is likely the consequence of defective OPC recruitment during earlier phases of the disease, because (i) if the recruitment is too slow, OPCs reach the axons after what we define as ‘remyelination-permissive window’, and thus remain undifferentiated; and (ii) if the recruitment is inefficient, OPC density in the lesions remains below the threshold required for differentiation. Importantly, we highlight that OPC proliferation in MS lesions is scarce, which strongly suggests that repeated episodes of demyelination/remyelination (OPC differentiation) will deplete the lesional OPC pool unless perilesional OPCs are recruited. We also point out that surviving mature oligodendrocytes in a subtype of early MS lesions may actually prevent the recruitment of OPCs. Because it has been suggested that OPC-mediated remyelination may be more efficient than that by surviving oligodendrocytes, we suggest that stimulating OPC recruitment during active disease should benefit remyelination in multiple types of lesions, including those with spared oligodendrocytes. Finally, we review molecular determinants of OPC recruitment and suggest a potential therapeutically-relevant strategy to increase this process in patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
(2009) · doi:10.1007/978-3-540-29678-2 · Cited by 900
Altered human oligodendrocyte heterogeneity in multiple sclerosis
Jäkel, S., Agirre, E., Mendanha Falcão, A., van Bruggen, D., Lee, K. W., Knuesel, I., Malhotra, D., ffrench-Constant, C., Williams, A., & Castelo-Branco, G. (2019) · Nature · doi:10.1038/s41586-019-0903-2 · Cited by 854
Hughes, E. G., Kang, S. H., Fukaya, M., & Bergles, D. E. (2013) · Nature Neuroscience · doi:10.1038/nn.3390 · Cited by 808
Rejuvenation of Regeneration in the Aging Central Nervous System
Ruckh, J. M., Zhao, J.-W., Shadrach, J. L., van Wijngaarden, P., Rao, T. N., Wagers, A. J., & Franklin, R. J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.11.019 · Cited by 649
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis
Falcão, A. M., van Bruggen, D., Marques, S., Meijer, M., Jäkel, S., Agirre, E., Samudyata, Floriddia, E. M., Vanichkina, D. P., ffrench-Constant, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0236-y · Cited by 579
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Cited by
White matter aging and its impact on brain function
Groh, J., & Simons, M. (2025) · Neuron · doi:10.1016/j.neuron.2024.10.019 · Cited by 124
Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology
Zou, P., Wu, C., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00385-7 · Cited by 97
“Previous studies have found that impaired OPC differentiation is the leading cause of remyelination failure in various neurogenerative diseases, including multiple system atrophy, amyotrophic lateral sclerosis, and MS [169, 213–215].”
BackgroundCRISPR-edited human ES-derived oligodendrocyte progenitor cells improve remyelination in rodents
Wagstaff, L. J., Bestard-Cuche, N., Kaczmarek, M., Fidanza, A., McNeil, L., Franklin, R. J. M., & Williams, A. C. (2024) · Nature Communications · doi:10.1038/s41467-024-52444-w · Cited by 30
“We know that 30% of MS demyelinated lesions contain low numbers of OPCs 8 – 10 , suggesting poor recruitment to lesions, and that post-mortem brain samples from people with progressive MS generally have fewer OPCs 11,12 .”
Remyelination in multiple sclerosis from the miRNA perspective
Maciak, K., Dziedzic, A., & Saluk, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1199313 · Cited by 28
Kumar Podder, A., Mohamed, M. A., Seidman, R. A., Tseropoulos, G., Polanco, J. J., Lei, P., Sim, F. J., & Andreadis, S. T. (2024) · Science Advances · doi:10.1126/sciadv.adk9918 · Cited by 22
Metadata
- Authors
- Tepavčević, V., & Lubetzki, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-10
- Volume
- 145
- Issue
- 12
- Pages
- 4178-4192
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4295269662
- Cited by
- 108
- References
- 38
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? https://app.cochat.ai/papers/10.1093/brain/awac307
- The paper
- Tepavčević, V., & Lubetzki, C. (2022). Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Brain. https://doi.org/10.1093/brain/awac307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.